A Clinical and Histopathological Study of Drug Eruptions Caused by STI571

Korean Journal of Dermatology

Volumn 41, Issue 10, 2003, Pages 1291-1296

  Oh, Chan Seok ^a   Park, Hyun Jeong ^a   Lee, Jun Young ^a   Cho, Baik Kee ^a   Kim, Dong Wook ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Drug euption; STI571

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DIARRHEA; DRUG ERUPTION; EOSINOPHIL; ERYTHEMA MULTIFORME; ERYTHEMA MULTIFORME LIKE ERUPTION; EXANTHEMATOUS ERUPTION; EXOCYTOSIS; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LATENT PERIOD; MALE; PROVOCATION TEST; RASH; SYMPTOMATOLOGY; URTICARIA; URTICARIAL ERUPTION;

EID: 0242410736     PISSN: 04944739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Boutin JA. Tyrosine protein kinase inhibition and cancer. Int J Biochem 1994;26:1203-1226
2. Renshaw MW, Mc Whirter JR, Wang JY. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 1995;15:1286-1293
3. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS et al. Stevens-Johnson syndrome after treatment with STI571. Br J Haematol 2002;117:620-622
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese, SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042
5. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatol 2001;203:57-519
6. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with Imatinib. Dermatology 2002;205:172-173
7. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An Algorithm for the operational assessment of adverse drug reactions. JAMA 1979;242:623-632
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM. Efficay and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
9. Brouard M. Cutaneous reactions to STI571. N Engl J Med 2001;345:618-619
10. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 66:1298-1304
11. Koeffler HP, Golde DW. Chronic myeloid leukemia-New concepts. N Engl J Med 1981;304:1201-1209,1269-1274
12. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM et al. Severe periorbital edema secondary to STI571. Cancer 2002;95:881-887
13. Simon AJR, Stephen G, O'Brien, Lucy CCM. Managing cutaneous reactions to imatinib therapy. Blood 2002;100:3434-3435